GGrantIndex
Sort

141,003 grants matching cytokine

HIV and Global Drug Therapies: Peripheral Neuropathy Complications and Mechanisms

$674,721
Cecilia M Shikuma · University Of Hawaii At Manoa · R01 · FY2009 · NS

Erythroid Self-Renewal

$674,713
James Palis · University Of Rochester · R01 · FY2025 · HL

CEBPD-Mediated Mechanisms of Glucocorticoid Insensitivity in Severe Asthma

$674,703
Blanca E Himes · University Of Pennsylvania · R01 · FY2017 · HL

Mechanisms of sensitization in High Risk Corneal Grafts

$674,667
Reza Dana · Schepens Eye Research Institute · R01 · FY2015 · EY

Central & peripheral body temperature in VLBW preterm infants during the neonatal period: Relationship to neonatal infection and necrotizing enterocolitis

$674,636
Robin Britt Dail · University Of South Carolina At Columbia · R01 · FY2018 · NR

Pathogenesis of lung injury mediated by lung-restricted antibodies

$674,627
Ankit Bharat · Northwestern University At Chicago · R01 · FY2024 · HL

Defining adaptive immune responses to Mtb-infection and TB disease among young children with and without HIV-exposure

$674,625
Christina Louise Lancioni · Oregon Health & Science University · R01 · FY2022 · AI

Novel Approach to Stabilize Atherosclerotic Plaque in Carotid Artery

$674,605
Devendra K. Agrawal · Western University Of Health Sciences · R01 · FY2021 · HL

GENETIC ANALYSIS OF ZEBRAFISH EMBRYO DEVELOPMENT

$674,545
Pu Paul Liu · National Human Genome Research Institute · Z01 · FY2008 · HG

Applying a Human Liver Microphysiology System to Develop Therapeutic Strategies for Non-Alcoholic Fatty Liver Disease (NAFLD)

$674,545
D. Lansing Taylor · University Of Pittsburgh At Pittsburgh · R01 · FY2020 · DK

TNFR1 in the regulation of autoinflammatory diseases

$674,536
Richard M Siegel · National Institute Of Arthritis And Musculoskeletal And Skin Diseases · ZIA · FY2011 · AR

Occurrence and Outcome of Dual HIV-1 Infection

$674,477
James Ivan Mullins · University Of Washington · R37 · FY2014 · AI

Expression signatures of TB-specific memory responses within the human lung

$674,453
Richard F Silver · Case Western Reserve University · R01 · FY2013 · HL

Project 1 - System Biological Analyses of Innate Responses to Vaccination

$674,422
Bali Pulendran · Emory University · U19 · FY2017 · AI

The Role of Group 3 Innate Lymphoid cells (ILC3) in Tuberculosis

$674,402
Shabaana A. Khader · Washington University · R01 · FY2019 · AI

The Role of Group 3 Innate Lymphoid cells (ILC3) in Tuberculosis

$674,402
Shabaana A. Khader · Washington University · R01 · FY2021 · AI

The Role of Group 3 Innate Lymphoid cells (ILC3) in Tuberculosis

$674,402
Shabaana A. Khader · Washington University · R01 · FY2020 · AI

Role of the Omentum in the Treatment of Morbid Obesity

$674,360
Vanderbilt University · R01 · FY2005 · DK

Resilience Endotype-derivation through Parsimonious Analysis and causal Inference of Recovery from Acute Respiratory Distress Syndrome (REPAIR-ARDS)

$674,351
Rishikesan Kamaleswaran · Duke University · R01 · FY2025 · HL

Signal Transduction by Tyrosine Phosphorylation

$674,327
Tony R. Hunter · Salk Institute For Biological Studies · R01 · FY2016 · CA

Signal Transduction by Tyrosine Phosphorylation

$674,327
Tony R. Hunter · Salk Institute For Biological Studies · R01 · FY2018 · CA

Signal Transduction by Tyrosine Phosphorylation

$674,327
Tony R. Hunter · Salk Institute For Biological Studies · R01 · FY2017 · CA

Fetal-Derived Exosome Cargos in Maternal Blood to Predict Fetal Alcohol Syndrome

$674,295
Michael Edgar Selzer · Temple Univ Of The Commonwealth · R01 · FY2025 · AA

A Phase 1 Study of Patient-Derived Multi-Tumor Associated Antigen Specific T Cells (MT-601) Administered to Patients with Metastatic Pancreatic Cancer following frontline FOLFIRINOX

$674,275
Juan Fernando Vera · Marker Therapeutics, Inc. · R44 · FY2024 · CA

A Phase 1 Study of Patient-Derived Multi-Tumor Associated Antigen Specific T Cells (MT-601) Administered to Patients with Metastatic Pancreatic Cancer following frontline FOLFIRINOX

$674,275
Juan Fernando Vera · Marker Therapeutics, Inc. · R44 · FY2025 · CA